adequan polysulphated glycosaminoglycan injection 250mg/ml
elanco australasia pty ltd - glycosaminoglycan polysulfate - parenteral liquid/solution/suspension - glycosaminoglycan polysulfate emulsifiers & surfactants active 250.0 mg/ml - musculoskeletal system - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - degenerative aseptic joint disease | traumatic degenerative joint d
glycosaminoglycan polysulfate
elanco australasia pty ltd - glycosaminoglycan polysulfate - unknown - glycosaminoglycan polysulfate emulsifiers & surfactants active 0.0 - active constituent
glycosaminoglycan polysulfate
randlab australia pty ltd - glycosaminoglycan polysulfate - unknown - glycosaminoglycan polysulfate emulsifiers & surfactants active 0.0 - active constituent
adequan polysulfated glycosaminoglycan injection: 100mg per ml
elanco australasia pty ltd - glycosaminoglycan polysulfate - parenteral liquid/solution/suspension - glycosaminoglycan polysulfate emulsifiers & surfactants active 100.0 mg/ml - musculoskeletal system - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - degenerative aseptic joint disease | traumatic degenerative joint d
adequan i.a.- polysulfated glycosaminoglycan injection, solution
american regent, inc. - polysulfated glycosaminoglycan (unii: 268aw7000t) (polysulfated glycosaminoglycan - unii:268aw7000t) - polysulfated glycosaminoglycan 250 mg in 1 ml - adequan is recommended for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. do not use in horses showing hypersensitivity to polysulfated glycosaminoglycan. do not administer adequan in the face of joint sepsis.
adequan i.m.- polysulfated glycosaminoglycan injection, solution
american regent, inc. - polysulfated glycosaminoglycan (unii: 268aw7000t) (polysulfated glycosaminoglycan - unii:268aw7000t) - polysulfated glycosaminoglycan 100 mg in 1 ml - adequan® i.m. multi-dose is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. there are no known contraindications to the use of intramuscular polysulfated glycosaminoglycan.
adequan canine polysulfated glycosaminoglycan injection solution
elanco us inc. - polysulfated glycosaminoglycan (unii: 268aw7000t) (polysulfated glycosaminoglycan - unii:268aw7000t) - polysulfated glycosaminoglycan 100 mg in 1 ml
adequan i.m.- polysulfated glycosaminoglycan injection, solution
american regent, inc. - polysulfated glycosaminoglycan (unii: 268aw7000t) (polysulfated glycosaminoglycan - unii:268aw7000t) - adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. there are no known contraindications to the use of intramuscular polysulfated glycosaminoglycan.
adequan 100 mg/ml solution for injection
daiichi sankyo altkirch sarl - glycosaminoglycan polysulfate - solution for injection - 100 milligram(s)/millilitre - glucosaminoglycan polysulfate - horses - n.s.a.i.d.
adequan 250 mg/ml solution for injection
daiichi sankyo altkirch sarl - glycosaminoglycan polysulfate - solution for injection - 250 milligram(s)/millilitre - glucosaminoglycan polysulfate - horses - n.s.a.i.d.